Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?

Romain Baer1, Célia Cintas1, Nicole Therville1

  • 1Inserm, U1037, Université Toulouse III, Centre de Recherches en Cancérologie de Toulouse, Oncopole de Toulouse, F31037, Toulouse, France.

Advances in Biological Regulation
|July 14, 2015
PubMed

Insights

Targeting the PI3K/Akt pathway offers potential for pancreatic cancer treatment. This review explores the therapeutic promise of isoform-specific PI3K inhibitors for pancreatic adenocarcinoma, aiming to improve efficacy and reduce side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Pancreatic cancer remains a largely incurable solid malignancy with limited targeted therapy options.
  • The Phosphatidylinositol 3-Kinase/Akt (PI3K/Akt) signaling pathway is frequently dysregulated in various cancers, attracting significant pharmaceutical interest.
  • While Class I PI3K isoforms are crucial in physiology, their distinct roles in oncogenesis are not fully elucidated.

Purpose of the Study:

  • To review the therapeutic potential of targeting the PI3K/Akt pathway in pancreatic cancer.
  • To evaluate the relevance of targeting specific Class I PI3K isoforms for pancreatic adenocarcinoma treatment.
  • To discuss the advantages of isoform-specific PI3K inhibitors over pan-PI3K inhibitors, particularly regarding adverse effects.

Main Methods:

  • Literature review of studies on PI3K/Akt signaling in cancer.
  • Analysis of current clinical trials involving PI3K inhibitors.
  • Discussion of preclinical and clinical data regarding PI3K isoform-specific targeting in pancreatic cancer.

Main Results:

  • The PI3K/Akt pathway is a key target in oncology due to its frequent deregulation.
  • Small molecule PI3K inhibitors are under clinical investigation for various cancers.
  • The differential roles of PI3K isoforms in pancreatic cancer warrant further investigation for targeted therapy development.

Conclusions:

  • Targeting the PI3K/Akt pathway holds significant therapeutic potential for pancreatic cancer.
  • Isoform-specific PI3K inhibitors may offer a more effective and safer treatment strategy compared to pan-PI3K inhibitors.
  • Further research is needed to determine the clinical relevance of isoform-specific PI3K inhibition in pancreatic adenocarcinoma.
Keywords:
Acinar cell transformationCell signallingClass I isoformsGenetically modified mouse modelsMutant KrasPI3K/Akt pathwayPancreatic cancer

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K
Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

2.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.1K